We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AcelRX Pharmaceuticals Inc | NASDAQ:ACRX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.86 | 0.861 | 0.89 | 0 | 01:00:00 |
From Oct 2019 to Oct 2024
REDWOOD CITY, Calif., May 22, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that Vince Angotti, Chief Executive Officer, will be presenting and taking 1x1 meetings at the Jefferies 2018 Global Healthcare Conference.
Details of the event are as follows:
Jefferies 2018 Global Healthcare Conference
Date: Wednesday, June 6, 2018
Location: Grand Hyatt Hotel, New York
Presentation Time: 8:00 am ET, 5:00 am PT
The presentation will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as DZUVEO™ outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and Zalviso® (sufentanil sublingual tablet system, 15 mcg) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in hospitalized patients.
For additional information about AcelRx's clinical programs, please visit www.acelrx.com.
View original content with multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-jefferies-2018-global-healthcare-conference-300652846.html
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright 2018 PR Newswire
1 Year AcelRX Pharmaceuticals Chart |
1 Month AcelRX Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
